Findings

What do systematic reviews say?

697 questions · 708 findings · 47 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 263 · 37.1%GRADE not reported 12 · 1.7%Very low 146 · 20.6%Low 168 · 23.7%Moderate 98 · 13.8%High 21 · 3%

Oral magnesium pidolate vs placebo or no intervention

Adverse events: diarrhoea and headache · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 12 participants
Moderate

Oral magnesium pidolate vs placebo or no intervention

Adverse events: including serious adverse events, vaso‐occlusive crisis, gastrointestinal disorder, headache or migraine, upper respiratory tract infection, rash · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 36 participants
Moderate

Intravenous magnesium sulphate vs placebo

HRQoL score (Child‐reported PedsQL generic scale) at 1 week · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 202 participants
Low

Intravenous magnesium sulphate vs placebo

HRQoL score (Child‐reported PedsQL multidimensional fatigue scale) at 1 week · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 202 participants
Low

Intravenous magnesium sulphate vs placebo

HRQoL score (Child‐reported PedsQL sickle cell disease module) at 1 week · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 202 participants
Low

Intravenous magnesium sulphate vs placebo

Length of hospital stay · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 104 participants
Low

Intravenous magnesium sulphate vs placebo

Hypotension · people with sickle cell disease

Intravenous magnesium sulphate showed no clear difference in adverse effects: hypotension compared with placebo (low certainty).

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
RR 2.57 [0.5, 13.08]
2 studies · 306 participants
Low

Intravenous magnesium sulphate vs placebo

Adverse effects: warmth at infusion site · people with sickle cell disease

Intravenous magnesium sulphate may leads to higher adverse effects: warmth at infusion site compared with placebo (low certainty).

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
RR 13.26 [3.23, 54.4]
1 study · 202 participants
Low

Oral magnesium pidolate vs placebo or no intervention

Change in frequency of vaso‐occlusive painful crises (as measured by pain diary days with significant pain) · people with sickle cell disease

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Oral magnesium pidolate vs placebo or no intervention

Quality of life · people with sickle cell disease

The review found no eligible studies for this question.

1 finding from 1 review

Magnesium for treating sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

Self‐reported pain relief ‐ NPSI: ranges from 0 to 100. Higher scores are indicative of neuropathic pain. · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Self‐reported pain relief ‐ S‐LANSS: Possible total scores range from 0 to 24, and a score of 12 or higher is indicative of neuropathic pain. · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Pregabalin vs placebo

Patient Global Impression of Change · adults and children with sickle cell disease experiencing neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

Time to improvement of symptoms · adults and children with sickle cell disease experiencing neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

QoL · adults and children with sickle cell disease experiencing neuropathic pain

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 16 participants
Very low

Pregabalin vs placebo

Quality of sleep · adults and children with sickle cell disease experiencing neuropathic pain

The review found no eligible studies for this question.

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Pregabalin vs placebo

Treatment‐related adverse effects · adults and children with sickle cell disease experiencing neuropathic pain

It is very uncertain whether summary of findings ‐ Pharmacological intervention (pregabalin) changes treatment‐related adverse effects compared with placebo (very low certainty).

1 finding from 1 review

Interventions for treating neuropathic pain in people with sickle cell disease 2019 · Cochrane Headline outcomes only
RR 1.33
1 study · 22 participants
Very low

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Number of immediate (less than 24 hours) and delayed (24 hours to 10 days) postoperative bleeding episodes requiring intervention · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Immediate (<24 h) and delayed (24 h to 10 days)
This outcome was not reported in either of the trials.
0 studies
No studies found

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic acid) vs Placebo, no intervention or usual care (with or without placebo)

Side effects or other adverse events · People with haemophilia (A or B) undergoing minor oral surgery or dental extractions

Antifibrinolytic therapy (tranexamic acid or epsilon aminocaproic… showed no clear difference in side effects or other adverse events compared with placebo, no intervention or usual care (with or without placebo) (low certainty).

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in patients with haemophilia or Von Willebrand disease… 2019 · Cochrane All outcomes
Up to 10 days postoperative
RD 0.034 [-0.32, 0.38]
2 studies · 59 participants
Low

Antifibrinolytic therapy - locally-applied tranexamic acid (TXA) mouthwash/solution (SoF eligibility: TXA or EACA; all included trials used topical TXA) vs Placebo mouthwash

Number of thromboembolic complications · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…

The review found no eligible studies for this question.

1 finding from 1 review

Antifibrinolytic therapy for preventing oral bleeding in people on anticoagulants undergoing minor oral surgery or… 2018 · Cochrane All outcomes
no estimate extracted
0 studies
No studies found